Advanced

Positron emission tomography in malignancies of the liver, pancreas and biliary tract - indications and potential pitfalls.

Ansari, Daniel LU ; Keussen, Inger LU and Andersson, Roland LU (2013) In Scandinavian Journal of Gastroenterology 48(3). p.259-265
Abstract
Abstract Malignancies of the hepato-pancreatico-biliary (HPB) system are relatively common and generally characterized by a dismal prognosis. Positron emission tomography (PET) is a functional imaging technique that has emerged as an important modality in oncological decision-making. The principal radiopharmaceutical in PET imaging is the glucose analog (18)F-fluorodeoxyglucose, which is able to detect altered glucose metabolism in malignant tissue. PET is typically used in conjunction with computed tomography (CT), and previous studies have supported several uses of PET/CT in HPB malignancies, including staging, differential diagnostics and monitoring of treatment response and progress of disease. A review of PET/CT in the context of HPB... (More)
Abstract Malignancies of the hepato-pancreatico-biliary (HPB) system are relatively common and generally characterized by a dismal prognosis. Positron emission tomography (PET) is a functional imaging technique that has emerged as an important modality in oncological decision-making. The principal radiopharmaceutical in PET imaging is the glucose analog (18)F-fluorodeoxyglucose, which is able to detect altered glucose metabolism in malignant tissue. PET is typically used in conjunction with computed tomography (CT), and previous studies have supported several uses of PET/CT in HPB malignancies, including staging, differential diagnostics and monitoring of treatment response and progress of disease. A review of PET/CT in the context of HPB malignancies will be presented, including indications and potential pitfalls. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Scandinavian Journal of Gastroenterology
volume
48
issue
3
pages
259 - 265
publisher
Taylor & Francis
external identifiers
  • wos:000315313400001
  • pmid:23148675
  • scopus:84875740508
ISSN
1502-7708
DOI
10.3109/00365521.2012.704936
language
English
LU publication?
yes
id
18765df4-82a5-4552-9df3-13a5a1f1563c (old id 3218990)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/23148675?dopt=Abstract
date added to LUP
2012-12-03 15:08:01
date last changed
2019-01-06 03:55:34
@article{18765df4-82a5-4552-9df3-13a5a1f1563c,
  abstract     = {Abstract Malignancies of the hepato-pancreatico-biliary (HPB) system are relatively common and generally characterized by a dismal prognosis. Positron emission tomography (PET) is a functional imaging technique that has emerged as an important modality in oncological decision-making. The principal radiopharmaceutical in PET imaging is the glucose analog (18)F-fluorodeoxyglucose, which is able to detect altered glucose metabolism in malignant tissue. PET is typically used in conjunction with computed tomography (CT), and previous studies have supported several uses of PET/CT in HPB malignancies, including staging, differential diagnostics and monitoring of treatment response and progress of disease. A review of PET/CT in the context of HPB malignancies will be presented, including indications and potential pitfalls.},
  author       = {Ansari, Daniel and Keussen, Inger and Andersson, Roland},
  issn         = {1502-7708},
  language     = {eng},
  number       = {3},
  pages        = {259--265},
  publisher    = {Taylor & Francis},
  series       = {Scandinavian Journal of Gastroenterology},
  title        = {Positron emission tomography in malignancies of the liver, pancreas and biliary tract - indications and potential pitfalls.},
  url          = {http://dx.doi.org/10.3109/00365521.2012.704936},
  volume       = {48},
  year         = {2013},
}